Celerion has extensive experience in developing and validating assays focused on tobacco related research. With over 30 assays developed to support clinical studies, Celerion maintains the widest variety of exposure marker assays. Within the field of tobacco research, Celerion also has the largest fully validated (to meet GLP requirements) list of assays.
Celerion has also developed a number of biomarker assays including total aromatic amines, the lowest LLOQ available for 3-hydroxy benzo[a]pyrene (50 fg/mL), the lowest available LLOQ for total NNN (200 fg/mL), and the most selective nicotine equivalent in human urine assay available today.
As a proactive strategy Celerion is developing methods to quantitate 8 polycyclic aromatic hydrocarbons in human urine, propylene glycol in human exhalate and plasma, glycerine in human exhalate and plasma, and a series of panel assays measuring the biomarkers of multiple tobacco related disease states.
In addition to delivering world-class tobacco science, our bioanalytical laboratories lead the industry in validating assays that are compliant to regulated GLP/GCP guidelines. Celerion’s bioanalytical laboratories use fully validated data management systems that include a paperless electronic laboratory notebook. With a commitment to investing in the latest LC-MS/MS technology and robotics, Celerion delivers high-quality data that meet our clients’ timelines.